Letter to the Editor: Salidroside in ulcerative colitis - neuroimmune regulatory mechanisms and clinical translation prospects

Key Takeaways for GI Nurses

• Salidroside, a natural bioactive compound, is being investigated as an adjunct or alternative therapeutic approach for ulcerative colitis (UC), working through a novel enteric neuro-glial-immune pathway rather than traditional immunosuppression alone.
• The proposed mechanism involves activation of the cAMP-PKA-CREB signaling pathway and suppression of pathologically activated enteric glial cells (EGCs), suggesting a dual action on mucosal barrier repair and inflammation control.
• This research reinforces the growing recognition of the gut-nerve-immune axis in IBD pathogenesis, which may eventually influence how nurses assess and discuss disease flares, stress-related symptom exacerbation, and treatment expectations with patients.
• While still preclinical/early-stage, this line of research highlights potential future options for patients who experience steroid dependence, treatment resistance, or inability to maintain remission with current first-line therapies.

Clinical Relevance

For GI nurses managing UC patients, this editorial underscores a persistent clinical challenge: despite effective first-line agents such as 5-aminosalicylates, corticosteroids, and immunosuppressants, many patients struggle with long-term disease control. Steroid dependence, opportunistic infection risk, and difficulty sustaining remission are issues nurses encounter regularly in infusion suites, outpatient clinics, and endoscopy units during surveillance colonoscopies. Understanding emerging mechanisms like the enteric neuro-glial-immune network broadens the clinical picture of UC beyond simple mucosal inflammation, framing it as a condition influenced by the enteric nervous system and glial cell activity. This perspective may help nurses better contextualize patient-reported symptoms such as stress-triggered flares or visceral hypersensitivity, which are often dismissed as purely psychological but may have a neuroimmune biological basis.

From an operational standpoint, awareness of novel compounds like salidroside is valuable for nurses involved in patient education, especially as patients increasingly ask about complementary or natural therapies found through online research. Being able to discuss the current evidence level—emphasizing that these findings stem from preclinical studies and require further validation before clinical adoption—helps nurses manage expectations and reinforce adherence to evidence-based first-line treatments. Additionally, as IBD care increasingly emphasizes personalized and multi-target approaches, nurses in endoscopy and infusion settings should anticipate continued evolution in treatment paradigms, including possible future adjunct therapies targeting the gut-brain axis rather than inflammation alone.

This also has implications for nursing professional development. Staying informed about mechanistic research, even when not yet clinically actionable, strengthens nurses' ability to participate in multidisciplinary discussions, support patient counseling, and anticipate shifts in therapeutic protocols as translational research progresses from bench to bedside.

Bottom Line

This editorial highlights promising preclinical evidence that salidroside may help control UC-related inflammation and promote mucosal healing by targeting the enteric neuro-glial-immune axis—offering a potential future option for patients who do not respond well to current first-line therapies, though GI nurses should recognize this remains early-stage research requiring further clinical validation before real-world application.